Annovis Bio (ANVS) Return on Assets (2020 - 2026)
Annovis Bio (ANVS) posted Return on Assets of 0.02% for Q1 2026, down 43.14% sequentially from 0.02% in Q4 2025, and down 1.0% YoY from 0.02% in Q1 2025.
Annovis Bio (ANVS) Return on Assets (2020 - 2026) Analysis & Trends
Annovis Bio has reported Return on Assets for 7 years, with the latest figure at 0.02% in Q1 2026.
- Quarterly Return on Assets fell 1.0% year-over-year to 0.02% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.02% (down 1.0% YoY) and the FY2025 annual result came in at 0.02%, up 1.0% from the prior year.
- Return on Assets declined to 0.02% in Q1 2026 per ANVS's latest filing, from 0.02% in the prior quarter.
- Over five years, Return on Assets peaked at 0.0% in Q1 2022 and troughed at 0.07% in Q2 2024.
- A 5-year average of 0.02% and a median of 0.02% in 2025 frame the typical range for Return on Assets.
- The sharpest annual moves came in 2023 and 2025: Return on Assets decreased 5 bps in 2023, then climbed 5 bps in 2025.
- Over 5 years, Return on Assets stood at 0.01% in 2022, then plunged by 694 bps to 0.06% in 2023, then surged by 66 bps to 0.02% in 2024, then grew by 16 bps to 0.02% in 2025, then sank by 43 bps to 0.02% in 2026.
- According to Business Quant data, Return on Assets over the past three periods registered 0.02%, 0.02%, and 0.01% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | 0.00% |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 0.00% |
| 10 | Annovis Bio | 67.53 Mn | 67.53 Mn | - | -0.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.02% |
| Dec 31, 2025 | -0.02% |
| Sep 30, 2025 | -0.01% |
| Jun 30, 2025 | -0.01% |
| Mar 31, 2025 | -0.02% |
| Dec 31, 2024 | -0.02% |
| Sep 30, 2024 | -0.04% |
| Jun 30, 2024 | -0.07% |
| Mar 31, 2024 | -0.05% |
| Dec 31, 2023 | -0.06% |
| Sep 30, 2023 | -0.03% |
| Jun 30, 2023 | -0.01% |
| Mar 31, 2023 | -0.01% |
| Dec 31, 2022 | -0.01% |
| Sep 30, 2022 | -0.01% |
| Jun 30, 2022 | 0.00% |
| Mar 31, 2022 | 0.00% |
| Dec 31, 2021 | 0.00% |
| Sep 30, 2021 | 0.00% |
| Jun 30, 2021 | 0.00% |